Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.

Disseminated tuberculosis in a patient treated with biologics.

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Ileocolonic tuberculosis clinically, endoscopically, and radiologically mimicking Crohn's disease: disseminated infection after treatment with infliximab.

Radiological manifestations of pulmonary tuberculosis in patients subjected to anti-TNF-α treatment.

Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study.

Tuberculosis and TNFα antagonists--what are we missing?

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs.

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.

Screening for tuberculosis infection prior to initiation of anti-TNF therapy.

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.